Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.
D017151:Antibodies, Catalytic / Q000737:chemistry / Q000378:metabolism*; D001711:Biotransformation; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics*; D015195:Drug Design; D005990:Glycerol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000633:toxicity; D006801:Humans; D020128:Inhibitory Concentration 50; D011355:Prodrugs / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics*
D017151:Antibodies, Catalytic; D004337:Drug Carriers; D011355:Prodrugs; C000515:cremophor EL; D004317:Doxorubicin; D005990:Glycerol